New natural supplement brand launches first in women's wellness through every life stage... from postnatal to perimenopause
The brand has built a loyal community of +300,000 women who love their Food-Grown® supplements to support everything from better sleep, to energy to skin health and through all stages of life, from postnatal recovery to perimenopause.
Now, they're bringing their mission to life with the brand's very first London pop-up happening on July 30 and 31 in London.
One of the highlights of the pop-up is Wild Nutrition's new Weight Management Support supplement, a UK-first botanical formula designed to support metabolism, hormonal balance and energy, while nourishing the body.
Wild Nutrition's Weight Management Support capsules (£45.00, 90 capsules), a new formulation combining essential nutrients with Metabolaid®, a botanical complex now available in the UK which sold out in just 5 hours on launch day. Sign up to the waitlist to be the first to know when it lands again.
Designed with women in mind, the supplement brings together clinically studied ingredients like Lemon Verbena and Hibiscus, along with nutrients such as Chromium, Zinc, Magnesium and Vitamin B6, all aimed at supporting normal energy levels, blood sugar balance, and metabolic function.
This supplement changes the conversation around weight management. It's not about eating less, it's about nourishing more,' says Isabelle Nunn, Head of Nutrition at Wild Nutrition.
'This formula is about empowering women on their weight management journey to nourish their bodies.'
As interest in prescription-based weight management solutions like GLP-1 injections grows*, many women are turning to gentler options that focus on overall health rather than quick fixes.
'Wild Nutrition consistently set the standard in science-backed, nutrient support,' says Isabelle. 'There's an evolving weight management need in the UK we've heard first hand through our consultations - women saying they want to find ways to support their weight management naturally.'
Book a complimentary nutritional consultation to find out more.
To give you a taste of what's on offer at the pop-up event, on Wednesday July 30 from 5:30pm–8:30pm, Wild Nutrition is hosting a powerful and honest conversation about all sides of weight management, from style and confidence to movement, sex, and nutrition.
The panel, titled Redefining: Body, Balance and Breakthroughs, will be hosted by writer and podcaster Billie Bhatia, and features an inspiring line-up of voices.
Plus, as a bonus, the first 15 people to sign up for the panel will receive a goody bag worth £100, including the brand-new Weight Management Support supplement, before it next goes on sale in August.
on the 31st July at the pop up.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
22 minutes ago
- The Independent
Lidl issues urgent ‘do not eat' warning over popular product amid allergy fear
A major UK supermarket has issued a product recall with a 'do not eat' warning for one if its popular meals. Lidl GB has told consumers who bought the Red Hen 4 Tempura Chicken Steaks 380g to check whether they are part of the affected batch. The product is being recalled because milk has not been boldened in the ingredients section - with the supermarket warning this could pose a health risk to people intolerant to milk. 'Lidl GB is recalling the above-mentioned product due to milk not being in bold within the back of pack ingredients,' the supermarket said in its product recall notice. 'This may be a possible health risk for anyone with an allergy to milk. 'If you have bought the above product and have an allergy to milk we advise you not to eat it. 'Customers are asked to return this product to the nearest store where a full refund will be given.' The Food Standards Agency (FSA) said the product 'contains milk making it a possible health risk for anyone with an allergy or intolerance to milk or milk constituents'. 'Lidl is recalling the above product from customers and has been advised to contact the relevant allergy support organisations, which will tell their members about the recall,' the FSA added. 'The company has also issued a point-of-sale notice to its customers. These notices explain to customers why the product is being recalled and tell them what to do if they have bought the product.' The recall only applies to the packs with the following 'best before' dates: 11/12/2026 16/12/2026 22/12/2026 30/12/2026 16/01/2027
Telegraph
an hour ago
- Telegraph
Streeting should ‘channel Thatcher' and introduce prostate screening
Wes Streeting should 'channel Margaret Thatcher ' and introduce screening for prostate cancer without delay, one of the world's leading experts has said. Prof Jonathan Waxman, the founder of the charity Prostate Cancer UK, says the Health Secretary should learn from Thatcher's decision to introduce routine mammograms for women, which he said had saved 3,000 lives a year since they were introduced in 1988. The Telegraph has launched a campaign calling for the introduction of targeted screening for prostate cancer so those at high risk are automatically offered tests. Prostate Cancer UK has submitted evidence in favour of the policy to the UK National Screening Committee (UKNSC), which is currently considering the matter, with a decision expected later this year. Writing for The Telegraph, Prof Waxman said: 'There are interesting parallels between the prostate cancer and breast cancer screening stories. 'In the 1970s, before breast cancer screening was introduced by Government dictat, the medical consensus was, and, you have guessed it, that early diagnosis through screening mammography would not save lives. 'Mrs T, regardless of the medical consensus, waved her handbag at the doctors, ignored the consensus, and launched a screening programme for breast cancer. And the result? Screening mammography, together with treatment advances, has led to a massive improvement in survival from breast cancer. 'Before screening, just 65 per cent of patients with breast cancer survived and now over 80 per cent are cured as a result of early detection and better treatment. 'And how does this improvement manifest in the real world? Around 3,000 fewer women die each year in the UK from breast cancer than before the screening programme was introduced.' The emeritus professor at Imperial College London said Prostate Cancer UK led a consortium of men's health charities to collectively inform the committee on the importance of targeted screening for those at highest risk. But he said the NHS should act now so that GPs do far more to help men at risk of prostate cancer. He urged the NHS to rewrite its guidance so that family doctors are told to proactively start conversations with men about the PSA blood tests which can detect the disease. Current guidance says that men can ask for a test, though some GPs rebuff them. For younger men, including those with a family history of disease, offering a test is down to the clinical judgment of GPs about. In both cases, the onus is on patients to seek help in the first place, with many men including those with family histories of prostate cancer unaware they are at heightened risk of the disease. Prof Waxman said the NHS should rewrite its advice so that GPs are told that they should bring up prostate cancer with all patients who might be at extra risk. He added that the guidelines should suggest that GPs start conversations with men from the age of 45 at highest risk, so those who wish to can obtain a PSA test. 'This puts the power of informed choice back in the hands of men who need it the most and is a crucial step on the path to early diagnosis,' he says. In the past, screening advisers have rejected the practice on the grounds that the tests are too unreliable, and could result in too many men undergoing needless procedures. However, in recent years the back-up diagnostics used to confirm the initial test findings have significantly improved. A Department of Health and Social Care spokesman said: 'This Government has been clear we would like to see screening in place, but the decision must be evidence-led. 'The UK National Screening Committee is looking at this as a priority – including reviewing the evidence for screening men with a family history of prostate cancer. 'While the review is taking place we are getting on with improving cancer treatment and prevention, as well as funding tens of millions of pounds of research – GPs should consider risk factors and use clinical judgment when considering if patients need a prostate cancer test.' Prostate cancer is a lot more than a nuisance By Jonathan Waxman Sixty years ago, around 10,000 people in the UK were diagnosed annually with prostate cancer. Currently over 50,000 men are diagnosed each year and prostate cancer has the dreadful distinction of being the commonest cancer in men. In parallel, the number of prostate cancer deaths has increased from 3,300 to over 12,000 men annually. So, what to do? We can hope that the treatment of prostate cancer will improve and improve, and cures are found. Treatment is getting better. Thankfully, in 2025, well over 80 per cent of men with prostate cancer that has not spread beyond the prostate will be cured and the duration of survival for men with cancer that has spread has doubled compared with 25 years ago. These improvements have come because of modern medicine's marvellous miracles, developing from brilliant university research and big pharma's R & D. Prostate Cancer UK has invested over £120m in research over the years. But clearly despite the gloss of shiny medical breakthroughs, prostate cancer remains a fundamentally unpleasant problem, and a lot more than a nuisance. What can be done? Find it early, you say? Yes, that would seem logical. How do we do this? Well, if we want to find prostate cancer early then the obvious answer is to screen for prostate cancer. There is no UK screening programme for the early detection of prostate cancer, a cancer which is often without symptoms. The National Screening Committee is currently considering the role of screening for prostate cancer. Prostate Cancer UK has led a consortium of men's health charities to collectively inform the committee, which advises government, on the importance of targeted screening for those at highest risk. There are interesting parallels between the prostate cancer and breast cancer screening stories. In the 1970s, before breast cancer screening was introduced by Government dictat, the medical consensus was, and, you have guessed it, that early diagnosis through screening mammography would not save lives. Mrs T, regardless of the medical consensus, waved her handbag at the doctors, ignored the consensus, and launched a screening programme for breast cancer. And the result? Screening mammography together with treatment advances have led to a massive improvement in survival from breast cancer. Before screening, just 65 per cent of patients with breast cancer survived and now over 80 per cent are cured as a result of early detection and better treatment. And how does this improvement manifest in the real world? Around 3000 fewer women die in the UK from breast cancer each year than before the screening programme was introduced. To return to the debate on screening for prostate cancer. We are now at a critical inflection point in the history of prostate cancer screening. Last year, Prostate Cancer UK published research that showed prostate cancer diagnosis is safer and more accurate than ever before, and this in part is thanks to research the charity funded leading to MRI – Magnetic Resonance Imaging – being introduced into the diagnostic pathway. The National Screening Committee, under the iron baton of its excellent chair, is currently deliberating on the evidence for and against screening for prostate cancer and will issue a report this year. In heavily trailed remarks, Wes Streeting has indicated that he is in favour of screening but not for everyone, just for selective high risk groups of men. We at Prostate Cancer UK welcome this ministerial support, for it is also our view that there is a need for screening, and we believe the evidence is now there for targeted screening. We welcome his remarks at a time when we are about to launch TRANSFORM, a multi-centre screening trial using sophisticated technologies based on current diagnostic tools, an adaptive trial that is open to new screening tests. Prostate Cancer UK's trial invests £42m in a very long-term campaign to assess the survival benefits of modern screening methods. So, who are Mr Streeting's selective high risk groups of men at increased risk of prostate cancer? These are men with family histories of prostate cancer who constitute 1 to 5 per cent of all diagnosed patients, and black men, who have a one in four risk of prostate cancer, which is twice the risk of white men. What to do whilst we await the Screening Committee's conclusions? Currently GP guidelines concerning testing for prostate cancer are outdated. We urgently need these NHS guidelines updated to empower GPs to proactively start conversations about PSA testing with men from the age of 45 at highest risk. This puts the power of informed choice back in the hands of men who need it the most and is a crucial step on the path to early diagnosis. So, yes, prostate cancer is a bit of a nuisance, but let us see if we can do something about that nuisance. Prof Jonathan Waxman OBE is the founder and president of Prostate Cancer UK
Daily Mail
2 hours ago
- Daily Mail
Sir Chris Hoy explains why he feels 'lucky' after cancer diagnosis granted him 'the time to really appreciate life'
Sir Chris Hoy says his terminal cancer diagnosis has given him something many others never get: time to reflect, reset priorities and truly appreciate life. The Olympic legend, who revealed in October that he has stage four prostate cancer, has become a powerful voice for early detection and a living example that serious illness need not mean the end of meaningful living. Speaking to The Telegraph, Hoy reflected on friends who died suddenly, without the chance to say goodbye. He said: 'What would they have given for that? And therefore, for me, I think: "Well, aren't I lucky?" Look at the privilege I've got, the time to really appreciate life.' Hoy had no symptoms before his diagnosis. Then a sore shoulder led to a scan, which revealed a tumour. Further tests confirmed the cancer had spread to his bones. He was 47. Since then, Hoy, now 49, has thrown himself into raising awareness — particularly for men over 45 or those with risk factors like a family history. His own father was diagnosed with prostate cancer shortly before the London 2012 Olympics, but made a full recovery thanks to early detection. Hoy has also seen the impact of speaking out. NHS data shows a sharp rise in urological cancer referrals since his announcement, while Prostate Cancer UK has reported a major spike in risk assessments among men. He's not one to seek praise — in fact, he draws inspiration from others who spoke publicly about their diagnoses, including Rob Burrow and Doddie Weir. 'They stood up and they smiled and they used humour and they recognised that they could make a difference. I don't really see myself in the same vein as those two, but if I could have any impact at all…' Hoy is currently training for his September event, the Tour de 4, a mass-participation charity ride with routes for all abilities. He'll be tackling the toughest 56-mile route and says the goal is to challenge public perceptions of what living with stage four cancer can look like. He's also clear-eyed about the emotional toll of his diagnosis — including the fear, panic and difficult conversations with his children. But he credits his family, his support network, and the simple power of staying in the present for getting him through. 'It's the fear of the future that causes anxiety and stress for most people,' he said. 'So it's not allowing yourself to fast forward and try and predict what's going to happen because you never know.' Hoy's wife Sarra was diagnosed with multiple sclerosis just weeks after his own news. The couple have faced both challenges side by side, and Sarra is now training for Tour de 4 too. Between workouts, Hoy has returned to motor racing, recently driving at Le Mans with Top Gear's Chris Harris. But he insists the everyday moments matter most — time with his children, a good film, a shared laugh. He hopes his public platform will help others facing cancer feel less alone, and inspire men to get checked before it's too late. 'If my legacy is that less men are dying from prostate cancer, that would be incredible,' he concluded.
